Copyright: ©Author(s) 2026.
World J Clin Oncol. Sep 24, 2026; 17(9): 124416
Published online Sep 24, 2026. doi: 10.5306/wjco.124416
Published online Sep 24, 2026. doi: 10.5306/wjco.124416
Table 2 Best overall response, n (%)
| Anti-PD-1 plus cetuximab (n = 11) | Anti-PD-1 plus anlotinib (n = 10) | |
| Best overall response | ||
| Complete response | 1 (9.1) | 0 (0) |
| Partial response | 2 (18.2) | 4 (40.0) |
| Stable disease | 7 (63.6) | 6 (60.0) |
| Progressive disease | 1 (9.1) | 0 (0) |
| ORR, % | 27.3 | 40.0 |
| DCR, % | 90.9 | 100 |
- Citation: Wang JX, Wang TX, Song YT, Xu GH, Zhang YB, Zhang B. Efficacy of two programmed cell death 1 combination regimens in recurrent and/or metastatic head and neck carcinoma: A real-world retrospective study. World J Clin Oncol 2026; 17(9): 124416
- URL: https://www.wjgnet.com/2218-4333/full/v17/i9/124416.htm
- DOI: https://dx.doi.org/10.5306/wjco.124416